Back to the atlasDownload source notes

October 16, 2026 — scheduled focused research update

Home · Latest · Milestones

Focused review of 32 active condition topics in six groups. The retained Sleep hub supplies inherited history, not another monitoring assignment. Searches overlap seven days before the last full successful check; unfinished Sleep baselines also require preceding ninety-day context. Source dates remain separate from this review date. Worldwide/full-topic coverage remains incomplete and successful-check dates are preserved.

Findings

Coverage by topic

Whole-body MRI

Coverage: focused_incomplete. 0 newly recorded entries.

Searches: whole-body MRI screening outcomes HERCULES September October 2026; site:reddit.com "whole body MRI" "October" "2026" study; Live NCT06212479 and new registrations since 2026-09-05

Remaining gaps: Focused update; current page and named HERCULES registry checked, and the first-posted discovery query completed after retry. Its two hits were treatment trials using MRI measurements, not population whole-body screening programs. October 1 systematic review and previously saved commercial podcast claims were deduplicated. Actual October 14 SABI presentation materials, all UK Biobank follow-up analyses and worldwide screening guidance were not comprehensively appraised. No comprehensive no-news conclusion; retain the older full successful-check timestamp.

Informal sources and unresolved claims: Targeted indexed Reddit/podcast discovery did not supply a distinct attributable new development rumor. Commercial scan anecdotes and existing Durand/Prenuvo predictions were not converted into outcome evidence. Complete podcast audio and the October 14 SABI talks were not reviewed.

Sources checked:

Galleri and organ-specific cancer screening

Coverage: focused_incomplete. 2 newly recorded entries.

Searches: Galleri October 2026 FDA approval vote; site:grail.com October 2026 ESMO; Natera MCED October 9 2026 Breakthrough; Live saved registries and new screening registrations since 2026-09-05; site:reddit.com Galleri October 2026 approval

Remaining gaps: Focused update of current notes, saved trial records, sponsor/regulator leads and newly registered screening programs. All six initial named-record timeouts were resolved on retry. Broad discovery returned 146 records, of which the first 100 were retrieved; the remaining page and every organ-specific alternative were not appraised. Upcoming ESMO October 23–27 is still a meeting window, not delivered data. Galleri panel voting, SOARA and urine-VOC entries already saved October 13 were deduplicated. No full successful-check advancement.

Informal sources and unresolved claims: Targeted indexed Reddit and investor discussion searches revisited approval-timing speculation. No exact new FDA action date or primary approval document was established in this focused check. Existing approval-timing claim stays unconfirmed; advisory voting is not marketing authorization. Full investor audio/transcript coverage remains incomplete.

Sources checked:

Coverage: focused_incomplete. 3 newly recorded entries.

Searches: 2026-10-16: glp1 named-program updates, new human programs, results, safety/hold/discontinuation and approval searches; prioritize October 14–16.; 2026-10-16: glp1 original Reddit, podcast/talk and unresolved informal-signal searches.

Remaining gaps: Read current canonical scope, shared summaries, state and assigned topic notes. Bounded registry discovery covered September 5–October 16, 2026; prior October 13 findings were deduplicated. Full-topic successful-check dates remain unchanged.; Retrieved all 886 records across 9 pages of the bounded ClinicalTrials.gov query, plus 23 named records. Selected relevant new/changed protocols were appraised; downloading all records does not establish exhaustive safety/results review.; Europe PMC original-literature discovery failed with HTTP 503 for this topic. Targeted primary-source web searches supplied a partial fallback. Worldwide literature, regulators, international registries and complete original conference/podcast recordings remain incomplete.; SUNRISE sponsor initiation versus registry pending status was reconciled explicitly. Zenagamtide switching records were compared with October 13 snapshots. Other formulation/PK, body-composition and pediatric entries were screened selectively; routine registry edits were not promoted. Full international entrants, all holds/harms and original EASD discussion remain incomplete.

Informal sources and unresolved claims: Reopened original October 9 ENLIGHTEN-6 weekly thread: the saved appetite/skin/sleep account persists, without independent identity or causality verification; no repeat alert. SOLIS-1 direct thread retrieval again failed, so no status confirmation or retraction was inferred. Near-30% EloraTZP and future combination/titration/date claims remain unconfirmed. Wider EASD/Q&A/podcast source-chain review incomplete.

Sources checked:

Muscle building and preservation

Coverage: focused_incomplete. 0 newly recorded entries.

Searches: myostatin OR bimagrumab OR enobosarm OR muscle preservation OR deramiocel; trevogrumab COURAGE full publication; SAT-3247 current primary protocol; enobosarm Cantor original audio and trial-initiation follow-up; Targeted Reddit, podcast and informal new-program searches; saved unresolved-claim follow-up

Remaining gaps: All saved named registry records and every page of bounded September 5–October 16 CT.gov discovery were retrieved; 26 discovery records were screened selectively. Retrieval is not full appraisal. Worldwide registries, all publications/regulatory files, complete harms and original audio/transcripts remain incomplete. Prior full successful-check dates are preserved. COURAGE full in-press Lancet report and BELIEVE withdrawal-phase harms remain unrecovered; older sponsor results are not re-alerted.

Informal sources and unresolved claims: Targeted Reddit, interview, podcast and saved unresolved-claim searches were appraised selectively; original recordings and worldwide informal coverage remain incomplete. Routine anecdotes and reposts were not treated as new trial evidence. Saved enobosarm Cantor Phase 3 direction remains unconfirmed; original audio and actual initiation not verified.

Sources checked:

Longevity and healthspan trials

Coverage: focused_incomplete. 0 newly recorded entries.

Searches: 2026-10-16: longevity named-program updates, new human programs, results, safety/hold/discontinuation and approval searches; prioritize October 14–16.; 2026-10-16: longevity original Reddit, podcast/talk and unresolved informal-signal searches.

Remaining gaps: Read current canonical scope, shared summaries, state and assigned topic notes. Bounded registry discovery covered September 5–October 16, 2026; prior October 13 findings were deduplicated. Full-topic successful-check dates remain unchanged.; Retrieved all 53 records across 1 pages of the bounded ClinicalTrials.gov query, plus 13 named records. Selected relevant new/changed protocols were appraised; downloading all records does not establish exhaustive safety/results review.; Europe PMC original-literature discovery failed with HTTP 503 for this topic. Targeted primary-source web searches supplied a partial fallback. Worldwide literature, regulators, international registries and complete original conference/podcast recordings remain incomplete.; RESTOR, metformin, rapamycin, MAVRIC, ELITE and saved senolytic programs were refreshed. No extra formal result selected in this bounded review. AFAR TAME direct retrieval failed again; do not infer funding or actual initiation. Completed frailty/aging trials without new results remain pending, not negative results. Full worldwide geroscience and harms review remains incomplete.

Informal sources and unresolved claims: Reopened original Vitaei PEARL 24-month claim; offered citation mismatch and unconfirmed underlying follow-up remain unchanged, with no repeat alert. Informal longevity search results did not supply a new matching primary paper or attributable launch leak selected. Full recordings/transcripts remain incomplete.

Sources checked:

Localized fat removal and cellulite

Coverage: focused_incomplete. 0 newly recorded entries.

Searches: https://clinicaltrials.gov/api/v2/studies?query.term=%28CBL-514+OR+RZL-012+OR+tesamorelin+OR+cellulite+OR+submental+fat+OR+localized+adipose%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-16%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true; CBL-514 Phase 3 recruitment SUPREME October 2026; CBL514 new trials tesamorelin RZL-012 cellulite October 2026; site:reddit.com CBL514 trial October 2026; site:reddit.com cellulite trial October 2026

Remaining gaps: Read current canonical README, HOW_THIS_WORKS, WATCHLIST, catalog, state, LATEST, MILESTONES, LANDSCAPE and this entire topic page. Search window September 5–October 16 preserves overlap from September 12 full successful check; October 14–16 changes prioritized and all saved October 13 material deduplicated. Retrieved every page of bounded ClinicalTrials.gov discovery (100 returned records) and all 15 named records. Retrieved records were selectively appraised; incidental matches excluded. Do not advance full successful-check timestamp.; CBL-514 SUPREME-01 NCT07140939 remains recruiting, 320 planned, actual start September 1, 2026, July 2027 primary and September 2027 final completion estimates; record last posted September 22. No new Phase 3 efficacy, recruitment-completion announcement, or second newly registered pivotal study verified. Caliway news index still returns the saved October 2 MRI/EASD material and September 23 first-dosing announcement. Do not infer enrollment counts from recruitment status.; RZL-012 China Phase 3 report and year-end filing forecast, CBL-514 MRI findings, tesamorelin and cellulite records were deduplicated against current canonical history. Changes in subcutaneous, visceral and liver fat remain separate from weight loss and clinical outcomes. Broad discovery includes incidental lifestyle/other-condition records; retrieval does not establish a complete entrant census.; International registries, every aesthetic device/procedure, complete conference appendices, and full-text rare-harm review remain incomplete; no new result selected from the bounded searches is not a claim of no news.

Informal sources and unresolved claims: Targeted Reddit queries for CBL-514/CBL514, cellulite and October 2026 plus named-source searches did not yield a selected new specific informal claim. Indexed search is incomplete, including unindexed comments and audio; no claim that rumors are absent.

Sources checked:

Broad cardiovascular prevention, lipids and screening

Coverage: focused_incomplete. 0 newly recorded entries.

Searches: 2026-10-16: cardiovascular named-program updates, new human programs, results, safety/hold/discontinuation and approval searches; prioritize October 14–16.; 2026-10-16: cardiovascular original Reddit, podcast/talk and unresolved informal-signal searches.

Remaining gaps: Read current canonical scope, shared summaries, state and assigned topic notes. Bounded registry discovery covered September 5–October 16, 2026; prior October 13 findings were deduplicated. Full-topic successful-check dates remain unchanged.; Retrieved all 572 records across 6 pages of the bounded ClinicalTrials.gov query, plus 19 named records. Selected relevant new/changed protocols were appraised; downloading all records does not establish exhaustive safety/results review.; Europe PMC original-literature discovery failed with HTTP 503 for this topic. Targeted primary-source web searches supplied a partial fallback. Worldwide literature, regulators, international registries and complete original conference/podcast recordings remain incomplete.; Named VERVE/PCSK9/Lp(a), plaque and outcomes studies were refreshed without a selected new result. Newly registered folate-PET vascular-inflammation imaging is not an asymptomatic screening-outcome trial and was not promoted. LDL surrogate, prevention population and clinical outcomes remain separate. Worldwide safety/approval and source-video coverage are incomplete.

Informal sources and unresolved claims: Targeted PCSK9, LDL and Lp(a) informal searches surfaced older discussions and recycled projections, with no new attributable development rumor selected. Full original lipid podcasts/Q&A remain unreviewed; this is a coverage gap, not a no-rumors conclusion.

Sources checked:

Alzheimer's screening and therapies

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: Alzheimer October 14 2026 trial; Alzheimer October 15 2026 trial; Major Alzheimer prevention trial first participant October 15 2026 Banner; Clinical Meaningfulness of Donanemab correction October 8 2026; Live saved registries and new Alzheimer registrations since 2026-09-05; site:peterattiamd.com michaeldavidson obicetrapib Alzheimer; site:reddit.com Alzheimer October 2026 trial

Remaining gaps: Focused prevention/development update, with saved registries and all 38 discovery records retrieved. Added the investigator-announced first randomization in API-2, whose live registry was fetched separately. Previously saved PLASMAR, AHEAD, ultrasound/vaccine and SPINOZA entries were deduplicated. The October 8 Neurology Clinical Practice correction/replacement of a donanemab meaningfulness analysis was located by its journal index, but the correction text could not be retrieved; do not infer its substance. Full anti-amyloid label/ARIA/recall inventories, assay comparative utility and paid interviews remain incomplete. No full successful-check advancement.

Informal sources and unresolved claims: Indexed original October 10 Reddit/NYT discussion and Attia–Davidson public episode material were checked as leads. Neither provides new randomized confirmation of obicetrapib dementia prevention. SPINOZA remains a biomarker-focused registered program; the saved clinical-prevention hypothesis stays unconfirmed. Full paid transcript and podcast census remain incomplete.

Sources checked:

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: psilocybin October 15 2026 clinical trial FDA; Live saved registries and new psychedelic registrations since 2026-09-05; site:compasspathways.com October 2026 NDA; site:reddit.com COMP360 October 16 2026 FDA; site:reddit.com/r/shroomstocks 44 81 October 2026

Remaining gaps: Focused clinical-development/safety update. Saved named records and all 13 new-registration discovery records were retrieved. PEARL administrative update was deduplicated. New Johns Hopkins impairment study is a registered human safety protocol, not therapeutic efficacy. Full worldwide psychedelic pipeline, every FDA docket submission, original ibogaine workshop recording and all paid talk transcripts were not reviewed. Existing FDA ibogaine deadline/IBOCARE and COMP360 speculation were not re-alerted. No full successful-check advancement.

Informal sources and unresolved claims: Indexed original October 14–15 shroomstocks discussion speculates about timing COMP360 submission/approval around awareness events; no official new date was established. The saved anonymous CNPV 44–81-day prediction remains unconfirmed. A CRPS participant post is an anecdote about entering a study, not a new controlled pain result. No duplicate rumor alert; full talk/podcast review incomplete.

Sources checked:

Mental-health treatments, SSRIs and newer antidepressants

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: MHRA introduces new safeguards antidepressant safety October 15 2026; Antidepressants updated safety communications October 15 2026 public assessment report; Live saved registries and new depression/anxiety/OCD/PTSD/bipolar/addiction registrations since 2026-09-05; site:reddit.com PSSD October 15 2026 MHRA; site:reddit.com antidepressant October 2026 trial

Remaining gaps: Focused safety and human-program discovery update. MHRA October 15 press release, Drug Safety Update, patient guidance and public assessment report were accessed. Saved named registries were retrieved; broad new-registration discovery returned 596 records, only the first 100 retrieved, so mental-health coverage is explicitly incomplete. Small SAINT memory pilot and LIFU-OCD imaging experiment were reviewed as protocol leads but not promoted to established clinical benefit. Prior PEACE, BALANSYA and WELTRUZA items were deduplicated. No full successful-check advancement.

Informal sources and unresolved claims: Targeted indexed Reddit safety/antidepressant searches mostly surfaced personal experiences and secondary reporting. These were not used to estimate PSSD incidence or infer efficacy. MHRA safety changes are an official regulatory communication, not a rumor. No distinct attributable new development rumor selected; full podcast/talk coverage incomplete.

Sources checked:

Bone health, joint preservation and cartilage repair

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: osteoporosis OR cartilage repair OR lorecivivint OR TG-C; new human bone/cartilage/fracture trial results; abaloparatide denosumab primary completion; Targeted Reddit, podcast and informal new-program searches; saved unresolved-claim follow-up

Remaining gaps: All saved named registry records and every page of bounded September 5–October 16 CT.gov discovery were retrieved; 112 discovery records were screened selectively. Retrieval is not full appraisal. Worldwide registries, all publications/regulatory files, complete harms and original audio/transcripts remain incomplete. Prior full successful-check dates are preserved. AGILI-C full five-year harms/reoperation tables and TG-C ACTiVION-I October disclosure remain unresolved; no outcome inferred from elapsed forecasts.

Informal sources and unresolved claims: Targeted Reddit, interview, podcast and saved unresolved-claim searches were appraised selectively; original recordings and worldwide informal coverage remain incomplete. Routine anecdotes and reposts were not treated as new trial evidence.

Sources checked:

Liver health and noninvasive assessment

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: 2026-10-16: liver named-program updates, new human programs, results, safety/hold/discontinuation and approval searches; prioritize October 14–16.; 2026-10-16: liver original Reddit, podcast/talk and unresolved informal-signal searches.

Remaining gaps: Read current canonical scope, shared summaries, state and assigned topic notes. Bounded registry discovery covered September 5–October 16, 2026; prior October 13 findings were deduplicated. Full-topic successful-check dates remain unchanged.; Retrieved all 144 records across 2 pages of the bounded ClinicalTrials.gov query, plus 13 named records. Selected relevant new/changed protocols were appraised; downloading all records does not establish exhaustive safety/results review.; Europe PMC original-literature discovery failed with HTTP 503 for this topic. Targeted primary-source web searches supplied a partial fallback. Worldwide literature, regulators, international registries and complete original conference/podcast recordings remain incomplete.; The new Kylo-0603 patient trial is the selected formal entrant. Prior TRUTH, ARO-INHBE, ALN-CIDEB and efimosfermin findings were deduplicated. Current EMA Wegovy overview still does not resolve the saved September MASH variation; no approval/rejection inferred from omission. Full papers/supplements, clinical-outcomes and noninvasive-test utility census remain gaps.

Informal sources and unresolved claims: Saved Wegovy CHMP omission inference revisited against EMA current page; outcome remains unconfirmed and no repeat alert. Targeted informal searches supplied no separate new original claim selected. Complete conference/investor audio and informal source census remain incomplete.

Sources checked:

Cancer treatment, vaccines and recurrence prevention

Coverage: focused_incomplete. 2 newly recorded entries.

Searches: FDA atezolizumab stage III mismatch repair deficient colon cancer October 8 2026; NEJMoa2507874 ATOMIC adverse events; JAMA Oncology NEONIPIGA October 15 2026; Live saved registries and new cancer-vaccine/treatment registrations since 2026-09-05; site:reddit.com/r/sellaslifesciences REGAL October 2026 80; site:ir.sellaslifesciences.com October 2026 REGAL

Remaining gaps: Focused cancer-treatment, recurrence and safety update. The missed October 8 FDA ATOMIC approval was checked against the regulator and the original March 25 paper; October 15 NEONIPIGA publication was appraised. Saved registries and 72 discovery records were retrieved; each record and the full worldwide oncology pipeline were not individually appraised. ESMO late-breaking abstracts and all ADC/cell/radiopharmaceutical entrants remain incomplete. Previously saved NRG-BR002, T-bren and LUTEON/ATLAS entries were deduplicated. No full successful-check advancement.

Informal sources and unresolved claims: Indexed original SELLAS October 5, 6, 11–15 discussions continue event-count modeling and imminent-readout speculation. The October 12 modeling thread predicts a December 24 announcement, while others predict earlier; these are incompatible anonymous estimates, not independent evidence. No official new REGAL final event/OS result was established in the checked sources; the saved imminent-event rumor remains unresolved. No repeated alert.

Sources checked:

Autoimmune disease and immune reset

Coverage: focused_incomplete. 3 newly recorded entries.

Searches: CAR T OR immune reset OR fenebrutinib OR Treg with lupus/myositis/MS/RA; rap-cel/zola-cel restart; FB102 full result tables; Mount Sinai IBD CAR-T initiation; Targeted Reddit, podcast and informal new-program searches; saved unresolved-claim follow-up

Remaining gaps: All saved named registry records and every page of bounded September 5–October 16 CT.gov discovery were retrieved; 35 discovery records were screened selectively. Retrieval is not full appraisal. Worldwide registries, all publications/regulatory files, complete harms and original audio/transcripts remain incomplete. Prior full successful-check dates are preserved.

Informal sources and unresolved claims: Targeted Reddit, interview, podcast and saved unresolved-claim searches were appraised selectively; original recordings and worldwide informal coverage remain incomplete. Routine anecdotes and reposts were not treated as new trial evidence. Saved Mount Sinai IBD CAR-T planning remains unconfirmed; the new BMS protocol does not confirm that institutional claim.

Sources checked:

Non-opioid pain treatments

Coverage: focused_incomplete. 0 newly recorded entries.

Searches: suzetrigine OR VX-993 OR onzotrigine OR LTG321 OR non-opioid; non-opioid human trials, current named protocols, chronic pain safety; Targeted Reddit, podcast and informal new-program searches; saved unresolved-claim follow-up

Remaining gaps: All saved named registry records and every page of bounded September 5–October 16 CT.gov discovery were retrieved; 58 discovery records were screened selectively. Retrieval is not full appraisal. Worldwide registries, all publications/regulatory files, complete harms and original audio/transcripts remain incomplete. Prior full successful-check dates are preserved. New named-program and postoperative-protocol checks did not supply a selected additional event; this is not a complete no-news conclusion.

Informal sources and unresolved claims: Targeted Reddit, interview, podcast and saved unresolved-claim searches were appraised selectively; original recordings and worldwide informal coverage remain incomplete. Routine anecdotes and reposts were not treated as new trial evidence. Journavx patient comments concern subjective experience or access, without independently verified development milestones.

Sources checked:

Kidney preservation and earlier detection

Coverage: focused_incomplete. 0 newly recorded entries.

Searches: 2026-10-16: kidney named-program updates, new human programs, results, safety/hold/discontinuation and approval searches; prioritize October 14–16.; 2026-10-16: kidney original Reddit, podcast/talk and unresolved informal-signal searches.

Remaining gaps: Read current canonical scope, shared summaries, state and assigned topic notes. Bounded registry discovery covered September 5–October 16, 2026; prior October 13 findings were deduplicated. Full-topic successful-check dates remain unchanged.; Retrieved all 409 records across 5 pages of the bounded ClinicalTrials.gov query, plus 15 named records. Selected relevant new/changed protocols were appraised; downloading all records does not establish exhaustive safety/results review.; Europe PMC original-literature discovery failed with HTTP 503 for this topic. Targeted primary-source web searches supplied a partial fallback. Worldwide literature, regulators, international registries and complete original conference/podcast recordings remain incomplete.; EASi-KIDNEY now lists 8,371 actual participants, but its previously saved sponsor futility/discontinuation notice remains authoritative for the development decision; active-not-recruiting registry wording is not a restart. October 15 NephJC show notes link an August 4 VISIONARY release, not new October eGFR data. Full finerenone/IgAN label status, farabursen protocol reconciliation, ASN tables and worldwide earlier-detection review remain incomplete.

Informal sources and unresolved claims: Opened original October 15 Freely Filtered/NephJC FIND-CKD show notes with named speakers and links to existing primary studies; full audio/transcript was not appraised, and no novel efficacy claim was inferred from the new episode date. Prior farabursen investigator/recruitment lead remains unreconciled globally. Full informal coverage remains incomplete.

Sources checked:

Hearing and vision preservation/restoration

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: 4D-150 October 2026 readout; site:ir.4dmoleculartherapeutics.com October 2026; Live saved registries and new hearing/retina/vision registrations since 2026-09-05; site:audiocure.com AC102 2026 hearing trial; site:reddit.com AC102 October 2026; site:reddit.com AC102 2027 hearing October 2026

Remaining gaps: Focused human-program and access update, with current vision conference findings deduplicated. Named trial records were retrieved; broad discovery returned 541 records, only the first 100 retrieved. Registered intratympanic extracellular-vesicle phase 3 program was appraised. SPI1005 expanded-access record is temporarily not available, so registration was not described as open access. October 21 4DMT investor day remains scheduled. The complete BRUNELLO/MCO-010 underlying tables, every inherited/acquired sensory pipeline, regulator labels and original conference recordings remain incomplete. No full successful-check advancement.

Informal sources and unresolved claims: Revisited targeted AC102/hearing rumor searches and official/registry leads. No official phase 3 tinnitus start or authenticated confirmation of the saved purported-email 2027 claim was established. Registration of a different sudden-hearing-loss intervention does not corroborate AC102. The saved rumor remains unconfirmed; full original podcast/audio coverage incomplete.

Sources checked:

Hair loss, restoration and graying

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: https://clinicaltrials.gov/api/v2/studies?query.term=%28alopecia+OR+hair+graying+OR+hair+greying+OR+hair+repigmentation%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-16%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true; PP405 AWAKEN October14 first patient dosed; BQ002 grey hair clinical trial October 2026; site:cosmohealthconfidence.com clascoterone October 2026 submission; Olumiant current prescribing information October2026 alopecia12+; site:reddit.com clascoterone October2026 2027

Remaining gaps: Read current canonical README, HOW_THIS_WORKS, WATCHLIST, catalog, state, LATEST, MILESTONES, LANDSCAPE and this entire topic page. Search window September 5–October 16 preserves overlap from September 12 full successful check; October 14–16 changes prioritized and all saved October 13 material deduplicated. Retrieved every page of bounded ClinicalTrials.gov discovery (104 returned records) and all 20 named records. Retrieved records were selectively appraised; incidental matches excluded. Do not advance full successful-check timestamp.; Pelage October 14 first-dose confirmation and a separate women's Phase 2 forecast are material additions beyond the previously saved AWAKEN recruiting registry. Older Phase 2a efficacy/safety language is repeated context, not a new result.; Current manufacturer Olumiant PDF is revised October 2026 and still indicates severe alopecia areata in adults and patients aged 12 years and older. The September 25 pediatric approval is already recorded in the October 2 note; no duplicate approval finding. Adult approval dates to 2022; no ordinary androgenetic-alopecia approval was established. October warning-section revision dates were observed, but without a prior-label comparison no newly discovered risk is asserted.; BioCopper NCT07839494 October 15 update remains not yet recruiting, 88 planned; contact/instruction/eligibility edits do not establish new efficacy or a completed trial. November 2026 start and July 2027 completion remain estimates.; AWAKEN, HEADLINE, VDPHL01, GT20029, HU045 and named AA records refreshed without duplicate alerts. Complete Kintor international releases, every updated label, unregistered programs, full safety census and full audio/transcript coverage remain gaps.

Informal sources and unresolved claims: Original BQ-002 and clascoterone timing threads revisited with sponsor text. Both timing claims remain unconfirmed without a material status transition. October 14 PP405 repost is dependent on the original Pelage release; wording suggesting a final trial is not proof that all regulatory work is finished. Broad October comments repeating 2027 launch optimism are not independent confirmation. No repeat rumor alert.

Sources checked:

Skin aging, laxity and regeneration

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: https://clinicaltrials.gov/api/v2/studies?query.term=%28skin+aging+OR+skin+laxity+OR+skin+rejuvenation+OR+KB304+OR+microcoring%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-16%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true; skin rejuvenation trial results October2026 aesthetic; A Randomized No-Treatment SB-NASHA décolletage DOI5381; site:galderma.com Skinboosters 2026 FDA; site:accessdata.fda.gov SB-NASHA 2026; site:reddit.com skin aging October2026 study

Remaining gaps: Read current canonical README, HOW_THIS_WORKS, WATCHLIST, catalog, state, LATEST, MILESTONES, LANDSCAPE and this entire topic page. Search window September 5–October 16 preserves overlap from September 12 full successful check; October 14–16 changes prioritized and all saved October 13 material deduplicated. Retrieved every page of bounded ClinicalTrials.gov discovery (78 returned records) and all 10 named records. Retrieved records were selectively appraised; incidental matches excluded. Do not advance full successful-check timestamp.; Newly appraised October 9 SB-NASHA randomized publication is an evidence upgrade and a new-to-watch clinical comparison; registry results were already posted July 15. Preserve publication versus first disclosure dates.; Sofwave October 5 release repeats the June 1 paper already saved October 9; no duplicate news. Newly posted October 14–16 studies include small single-arm MD60000 and completed thread/cream pilots without results; not promoted as demonstrated benefit. MD60000 registry has same-day estimated start and primary completion and requires clarification before calendar use.; No current U.S. approval for the precise SB-NASHA décolletage formulation/indication was verified. Manufacturer brands and paper-era availability do not settle current FDA status. Full FDA/IFU census, complete non-U.S. procedures, every publication and rare-event long-term safety remain incomplete.

Informal sources and unresolved claims: Reddit skin-aging/rejuvenation queries and primary/podcast discovery reviewed; Sofwave promotional episode and sponsor announcement repeat the already saved study. No new specific high-value claim selected. Full audio, transcripts and unindexed conversations were not exhaustively reviewed.

Sources checked:

Scar prevention, treatment and stretch marks

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: https://clinicaltrials.gov/api/v2/studies?query.term=%28scar+OR+keloid+OR+stretch+mark+OR+verteporfin+OR+siSPARC%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-16%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true; scar prevention clinical trial October2026 human randomized; site:reddit.com scar verteporfin October2026; shock wave therapy partial-thickness forearm burn scars electronic publication date

Remaining gaps: Read current canonical README, HOW_THIS_WORKS, WATCHLIST, catalog, state, LATEST, MILESTONES, LANDSCAPE and this entire topic page. Search window September 5–October 16 preserves overlap from September 12 full successful check; October 14–16 changes prioritized and all saved October 13 material deduplicated. Retrieved every page of bounded ClinicalTrials.gov discovery (246 returned records) and all 11 named records. Retrieved records were selectively appraised; incidental matches excluded. Do not advance full successful-check timestamp.; New October 16 SYLKE versus Prineo/paper-tape randomized surgical-dressing trial directly tracks scar quality and adhesive injury; planned research, no outcomes.; SCARFREE-001 NCT07488988 remains not yet recruiting, 12 planned, October 2026 estimated start, August/November 2028 primary/final estimates; October 5 registry refresh already saved. Do not infer dosing from the elapsed portion of October or from informal descriptions calling studies ongoing.; Newly surfaced burn shock-wave paper DOI10.1016/j.burns.2026.108116 was electronically published months earlier despite November issue; not a current conference result. No new alert. ScarASC NCT07635875 surfaced as a candidate but its full original record/publication was not appraised; retain a follow-up gap.; Full stretch-mark/device inventory, original international registries, mature scar-remodeling trials and complete safety/functional-outcome appraisal remain incomplete.

Informal sources and unresolved claims: October 13 comment in a FUT-scar thread speculates about verteporfin scarless regeneration; October 7 hydrogel discussion extrapolates from research. These are uncontrolled/animal-derived interpretations rather than new human efficacy; sourcing instructions excluded. Existing experimental reports were not treated as formal trial outcomes. No selected new status change.

Sources checked:

Facial volume restoration and contour

Coverage: focused_incomplete. 0 newly recorded entries.

Searches: https://clinicaltrials.gov/api/v2/studies?query.term=%28dermal+filler+OR+facial+volume+OR+facial+fat+graft+OR+nasolabial%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-16%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true; Belotero Volume October14 2026 available; Belotero Volume now available Merz USA; site:reddit.com Belotero October2026; Merz medical spa insider October6 2026 regenerative aesthetics

Remaining gaps: Read current canonical README, HOW_THIS_WORKS, WATCHLIST, catalog, state, LATEST, MILESTONES, LANDSCAPE and this entire topic page. Search window September 5–October 16 preserves overlap from September 12 full successful check; October 14–16 changes prioritized and all saved October 13 material deduplicated. Retrieved every page of bounded ClinicalTrials.gov discovery (98 returned records) and all 7 named records. Retrieved records were selectively appraised; incidental matches excluded. Do not advance full successful-check timestamp.; October 14 BELOTERO VOLUME (+) anticipated U.S. commercial-availability date is now elapsed. The original September 14 Merz release and news index still provide that forecast, with December 1 anticipated for INTENSE (+). No later sponsor announcement or verified dispensing/inventory established an actual national launch.; Primary clinic pages advertise expected October access or an October 14 booking offer but are not confirmation of stock or receipt of treatment. Keep availability unverified; do not label the product unavailable or the launch failed. FDA approval and physical availability remain distinct. Earlier May 19 VOLUME and July 9 INTENSE approvals are already saved.; October 6 AmSpa podcast article carries an incorrect September 14 approval date while describing the announcement; do not substitute it for FDA decision dates. Its broad regenerative-aesthetics remarks provide no controlled new benefit.; Full pivotal SSED/IFU reappraisal, every facial filler/fat-grafting entrant, comparative durability and rare vascular-event census remain incomplete.

Informal sources and unresolved claims: Belotero Reddit/clinic and AmSpa original podcast-summary discovery reviewed. Clinic booking/expected-access wording is a commercial informal signal, not verified stock; podcast does not establish a new outcome. Complete episode audio/transcript was not appraised.

Sources checked:

Pigmentation and uneven skin tone

Coverage: focused_incomplete. 0 newly recorded entries.

Searches: https://clinicaltrials.gov/api/v2/studies?query.term=%28melasma+OR+vitiligo+OR+hyperpigmentation+OR+solar+lentigines%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-16%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true; Immunomodulatory Effects of Fractional CO2 Laser Narrowband UVB 2026; DOI10.3390/ijms27209076 primary article retrieval; site:reddit.com melasma October2026 trial; vitiligo NCT new human trial October2026

Remaining gaps: Read current canonical README, HOW_THIS_WORKS, WATCHLIST, catalog, state, LATEST, MILESTONES, LANDSCAPE and this entire topic page. Search window September 5–October 16 preserves overlap from September 12 full successful check; October 14–16 changes prioritized and all saved October 13 material deduplicated. Retrieved every page of bounded ClinicalTrials.gov discovery (57 returned records) and all 10 named records. Retrieved records were selectively appraised; incidental matches excluded. Do not advance full successful-check timestamp.; October 15 first registry posting NCT07876323 describes a completed 30-participant Phase 2 split-face melasma study comparing eflornithine/hydroquinone/fluocinolone against tretinoin/hydroquinone/fluocinolone; actual study ended July 11, 2024, no posted results. Late registration is not a 2026 efficacy readout. Structured masking says none while narrative says participant/assessor blinding, requiring clarification.; October 13 IJMS article DOI10.3390/ijms27209076 title/version date verified, but primary HTML/XML retrieval failed (403) and no numerical outcome was appraised. A related September 1 Frontiers biomarker paper may concern an overlapping cohort. Do not infer visible durable repigmentation from biomarkers or count independent trials before full texts are compared.; POVOR, JAK/vitiligo, P114 and named pigmentation records deduplicated. Full melasma/lentigines devices, post-inflammatory pigmentation, non-U.S. registries, detailed safety and duration remain incompletely appraised.

Informal sources and unresolved claims: Targeted Reddit melasma/vitiligo/October queries did not identify a selected new source-attributable rumor. Publisher access gap remains explicit; unindexed comments and full podcasts/talks were not exhaustively reviewed.

Sources checked:

Acne and rosacea

Coverage: focused_incomplete. 0 newly recorded entries.

Searches: https://clinicaltrials.gov/api/v2/studies?query.term=%28acne+OR+rosacea+OR+denifanstat+OR+B244%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-16%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true; rosacea acne October14 2026 clinical trial pharma; site:aobiome.com October2026 B244 rosacea phase3; site:reddit.com Rosacea clinical trial recruiting October2026

Remaining gaps: Read current canonical README, HOW_THIS_WORKS, WATCHLIST, catalog, state, LATEST, MILESTONES, LANDSCAPE and this entire topic page. Search window September 5–October 16 preserves overlap from September 12 full successful check; October 14–16 changes prioritized and all saved October 13 material deduplicated. Retrieved every page of bounded ClinicalTrials.gov discovery (56 returned records) and all 13 named records. Retrieved records were selectively appraised; incidental matches excluded. Do not advance full successful-check timestamp.; October 15 remibrutinib NCT07681271 refresh remains recruiting, 100 planned; site/verification changes are not a new efficacy result. The Phase 2 BTK-inhibitor study is already saved; do not equate chronic-urticaria approval with rosacea approval.; October 13 toner result, B244 direction/timing, and prior DMT310/XYNGARI sponsor-plan correction are already saved. Broad acne/rosacea registry discovery returned 56 records, including incidental cohorts; no further material controlled result selected.; Complete sponsor/SEC/new-formulation census, all international registries, conference abstracts, full safety and complete podcast/transcript review remain gaps.

Informal sources and unresolved claims: Original October 7 r/Rosacea Ontario recruitment post revisited. It discusses a Phase 2 trial and speculates about future JAK agents; neither a clinic anecdote nor a BTK trial establishes JAK efficacy. No newly corroborated drug/date claim selected; full audio/transcript coverage incomplete.

Sources checked:

Dental alignment, regeneration and repair

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: https://clinicaltrials.gov/api/v2/studies?query.term=%28orthodontic+OR+aligner+OR+tooth+regeneration+OR+enamel+OR+periodontal+regeneration%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-16%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true; dental regeneration aligner clinical trial October2026; Long-term outcomes regenerative periodontal therapy orthodontic20year106799 online date; dentistry podcast October2026 regeneration; ALIGN-PBM SLCTR2026/026 registry

Remaining gaps: Read current canonical README, HOW_THIS_WORKS, WATCHLIST, catalog, state, LATEST, MILESTONES, LANDSCAPE and this entire topic page. Search window September 5–October 16 preserves overlap from September 12 full successful check; October 14–16 changes prioritized and all saved October 13 material deduplicated. Retrieved every page of bounded ClinicalTrials.gov discovery (152 returned records) and all 12 named records. Retrieved records were selectively appraised; incidental matches excluded. Do not advance full successful-check timestamp.; Appraised an older May 28 online 20-year periodontal-regeneration/orthodontics cohort despite its October issue. Baseline context only, not new October news; valuable because it measures tooth survival and complications rather than a regeneration marker.; October 15 EV registry update NCT07867067 remains not yet recruiting, 22 planned, no results; affiliation/formatting changes do not establish treatment. Other October 14–16 small registrations include orthodontic acceleration, bracket bone/root outcomes, extraction-site volume preservation and endodontics; no outcomes. Untested ridge preservation is not whole-tooth regeneration.; SLCTR/2026/026 ALIGN-PBM is pending, 34 planned in Oman, October 15 anticipated start with no first-enrollment date; it studies pain after aligner change, not total treatment duration, final bite, root/gum health or retention. Formal registry checked as a discovery example, not an efficacy claim.; Toregem primary Japanese Phase 1/2 record, first Phase IIa dosing, every directly printed/shape-memory aligner program, long-term retention and root/gum safety, and complete new-tooth efficacy remain unresolved.

Informal sources and unresolved claims: October 9 Very Dental Marco Maiolino episode description and October 13 ADA Smart AI episode listing inspected. These discuss preservation/workflows, not newly measured regeneration or orthodontic benefit; no timestamped result claim extracted and full audio/transcript not reviewed. Old tooth-regrowth launch forecasts remain unconfirmed.

Sources checked:

Allergy and airway disease

Coverage: focused_incomplete. 3 newly recorded entries.

Searches: asthma OR COPD OR food allergy OR chronic sinusitis human phases2/3; food/environmental allergy, acute-COPD and sinus trial results/new programs; Targeted Reddit, podcast and informal new-program searches; saved unresolved-claim follow-up

Remaining gaps: All saved named registry records and every page of bounded September 5–October 16 CT.gov discovery were retrieved; 153 discovery records were screened selectively. Retrieval is not full appraisal. Worldwide registries, all publications/regulatory files, complete harms and original audio/transcripts remain incomplete. Prior full successful-check dates are preserved. COPD SAPs and primary disclosure history were independently checked. ALIENTO registry versus paper p-value differs slightly without a verified explanation; full Lancet text remains inaccessible.

Informal sources and unresolved claims: Targeted Reddit, interview, podcast and saved unresolved-claim searches were appraised selectively; original recordings and worldwide informal coverage remain incomplete. Routine anecdotes and reposts were not treated as new trial evidence.

Sources checked:

Infectious-disease prevention and treatment

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: antibiotic OR bacteriophage OR vaccine OR antiviral human phases2/3; new antibiotics/phages/vaccine programs; Travelan primary paper and posted results; Targeted Reddit, podcast and informal new-program searches; saved unresolved-claim follow-up

Remaining gaps: All saved named registry records and every page of bounded September 5–October 16 CT.gov discovery were retrieved; 355 discovery records were screened selectively. Retrieval is not full appraisal. Worldwide registries, all publications/regulatory files, complete harms and original audio/transcripts remain incomplete. Prior full successful-check dates are preserved. New completion labels for VAX-31 and VYD2311 do not add results beyond earlier disclosures; future-antibiotic/phage worldwide coverage remains selective.

Informal sources and unresolved claims: Targeted Reddit, interview, podcast and saved unresolved-claim searches were appraised selectively; original recordings and worldwide informal coverage remain incomplete. Routine anecdotes and reposts were not treated as new trial evidence. Original adibelivir Reddit post describes an October 9 non-substantial CTIS modification whose contents were unavailable. That routine, unverified administrative inference was not promoted to an efficacy or approval rumor.

Sources checked:

Genetic screening and risk prediction

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: genetic screening October 15 2026 prospective; Live saved registries and new genomic/PRS/PGT registrations since 2026-09-05; site:reddit.com Nucleus October 2026 embryo; Nucleus Vitruvian 14 IQ October 2026

Remaining gaps: Focused implementation/discovery update after reading the current genetics page/state. Saved registries and all five hits from the narrow new-registration query were retrieved; ELISABETH was discovered through the overlapping cancer-screening query. Generation Study, WISDOM, international guidance, complete PGT-A/PGT-P literature, ancestry calibration and every pharmacogenomics utility study were not fully refreshed. Recent glossary page update dates were not counted as new evidence. No full successful-check advancement. PATHS-T1D (NCT07802496) still lists not yet recruiting after its October 15 estimated start; Nucleus PGT-P (NCT07841769) likewise remains not yet recruiting after October 1. No actual initiation is inferred from either elapsed estimate.

Informal sources and unresolved claims: Revisited indexed original September 27 Vitruvian Reddit discussion and current commercial-model context. The saved 14-point IQ claim still does not establish observed selected-offspring benefit; no meaningful status change was found in this bounded search. Original X remained an access gap from prior review; this run did not obtain it. No repeated rumor alert.

Sources checked:

Insomnia

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: 2026-10-16: sleep_insomnia named-program updates, new human programs, results, safety/hold/discontinuation and approval searches; prioritize October 14–16.; 2026-10-16: sleep_insomnia original Reddit, podcast/talk and unresolved informal-signal searches.

Remaining gaps: Read current canonical scope, shared summaries, state and assigned topic notes. Bounded registry discovery covered July 18–October 16, 2026; prior October 13 findings were deduplicated. Full-topic successful-check dates remain unchanged.; Retrieved all 291 records across 3 pages of the bounded ClinicalTrials.gov query, plus 6 named records. Selected relevant new/changed protocols were appraised; downloading all records does not establish exhaustive safety/results review.; Europe PMC original-literature discovery failed with HTTP 503 for this topic. Targeted primary-source web searches supplied a partial fallback. Worldwide literature, regulators, international registries and complete original conference/podcast recordings remain incomplete.; The new condition baseline remains incomplete. Preceding 90-day registry discovery and selected inherited pivotal context were checked; the full older clinical, label and behavioral/device evidence corpus has not been completed.; Selected eNightfall because it assesses clinical remission and follow-up rather than only laboratory physiology. Prior SMART, DARI-DREAM, COMISA-PEC and BELL-001 entries retained. Established medicine labeling, architecture endpoints and complete CBT-I/digital durability baseline remain incomplete.

Informal sources and unresolved claims: Targeted insomnia informal searches returned personal experiences and general prescribing discussions, without a distinct new formal development claim selected. TAK-360 nighttime-sleep account is recorded once under hypersomnolence. No rate or architecture effect inferred; full podcast/talk census incomplete.

Sources checked:

Obstructive sleep apnea

Coverage: focused_incomplete. 0 newly recorded entries.

Searches: 2026-10-16: sleep_apnea named-program updates, new human programs, results, safety/hold/discontinuation and approval searches; prioritize October 14–16.; 2026-10-16: sleep_apnea original Reddit, podcast/talk and unresolved informal-signal searches.

Remaining gaps: Read current canonical scope, shared summaries, state and assigned topic notes. Bounded registry discovery covered July 18–October 16, 2026; prior October 13 findings were deduplicated. Full-topic successful-check dates remain unchanged.; Retrieved all 148 records across 2 pages of the bounded ClinicalTrials.gov query, plus 6 named records. Selected relevant new/changed protocols were appraised; downloading all records does not establish exhaustive safety/results review.; Europe PMC original-literature discovery failed with HTTP 503 for this topic. Targeted primary-source web searches supplied a partial fallback. Worldwide literature, regulators, international registries and complete original conference/podcast recordings remain incomplete.; The new condition baseline remains incomplete. Preceding 90-day registry discovery and selected inherited pivotal context were checked; the full older clinical, label and behavioral/device evidence corpus has not been completed.; AD109 CHEST October 20 presentations remain future scheduled events; October 12 announcement was deduplicated. Named PAP-related metabolic and oral combination protocols were refreshed. No new AD109 effect or FDA decision inferred. The newly registered retrospective athlete CPAP study was not promoted as broad clinical evidence; comprehensive device/harms validation remains incomplete.

Informal sources and unresolved claims: Targeted oral-apnea/device informal searches did not provide a new attributable development signal selected. Existing AD109 scheduled presentation and approval-date speculation were deduplicated. Full original sleep conferences and device-access recordings remain incomplete.

Sources checked:

Narcolepsy & excessive sleepiness

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: 2026-10-16: sleep_hypersomnolence named-program updates, new human programs, results, safety/hold/discontinuation and approval searches; prioritize October 14–16.; 2026-10-16: sleep_hypersomnolence original Reddit, podcast/talk and unresolved informal-signal searches.

Remaining gaps: Read current canonical scope, shared summaries, state and assigned topic notes. Bounded registry discovery covered July 18–October 16, 2026; prior October 13 findings were deduplicated. Full-topic successful-check dates remain unchanged.; Retrieved all 27 records across 1 pages of the bounded ClinicalTrials.gov query, plus 8 named records. Selected relevant new/changed protocols were appraised; downloading all records does not establish exhaustive safety/results review.; Europe PMC original-literature discovery failed with HTTP 503 for this topic. Targeted primary-source web searches supplied a partial fallback. Worldwide literature, regulators, international registries and complete original conference/podcast recordings remain incomplete.; The new condition baseline remains incomplete. Preceding 90-day registry discovery and selected inherited pivotal context were checked; the full older clinical, label and behavioral/device evidence corpus has not been completed.; TAK-360, orexin agonist and ofatumumab records refreshed; the selected original patient account is informal only. Existing Orzeyful approval remains separate from conditional availability; no verified DEA scheduling/actual launch was found. Full labels, extensions, rare harms and original audio remain incomplete.

Informal sources and unresolved claims: Read original TAK-360/Kyra thread and selected one explicitly unconfirmed dose/sleep account, preserving unknown exact posting date. Original comment permalink separate fetch failed but text is visible in the parent thread. No formal clinical safety rate or approval/availability claim follows. Wider talks/podcasts remain incomplete.

Sources checked:

Circadian rhythm disorders

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: 2026-10-16: sleep_circadian named-program updates, new human programs, results, safety/hold/discontinuation and approval searches; prioritize October 14–16.; 2026-10-16: sleep_circadian original Reddit, podcast/talk and unresolved informal-signal searches.

Remaining gaps: Read current canonical scope, shared summaries, state and assigned topic notes. Bounded registry discovery covered July 18–October 16, 2026; prior October 13 findings were deduplicated. Full-topic successful-check dates remain unchanged.; Retrieved all 345 records across 4 pages of the bounded ClinicalTrials.gov query, plus 4 named records. Selected relevant new/changed protocols were appraised; downloading all records does not establish exhaustive safety/results review.; Europe PMC original-literature discovery failed with HTTP 503 for this topic. Targeted primary-source web searches supplied a partial fallback. Worldwide literature, regulators, international registries and complete original conference/podcast recordings remain incomplete.; The new condition baseline remains incomplete. Preceding 90-day registry discovery and selected inherited pivotal context were checked; the full older clinical, label and behavioral/device evidence corpus has not been completed.; Recovered September 29 tasimelteon sponsor topline closes a specific saved publication-access gap. Actual September completion and no registry results remain valid statements; saying no topline exists is no longer accurate. SUSTAIN and ICU studies refreshed without new results. Jet-lag hearing outcome, sustained phase/function evidence and full older baseline remain incomplete.

Informal sources and unresolved claims: Original Non-24/DSPD discussions include disability/access burden and personal timing responses, not new controlled efficacy or regulatory evidence. September tasimelteon topline was verified at the sponsor release rather than inferred from Reddit. Jet-lag hearing speculation remains unconfirmed; full audio incomplete.

Sources checked:

Restless legs syndrome

Coverage: focused_incomplete. 0 newly recorded entries.

Searches: 2026-10-16: sleep_restless_legs named-program updates, new human programs, results, safety/hold/discontinuation and approval searches; prioritize October 14–16.; 2026-10-16: sleep_restless_legs original Reddit, podcast/talk and unresolved informal-signal searches.

Remaining gaps: Read current canonical scope, shared summaries, state and assigned topic notes. Bounded registry discovery covered July 18–October 16, 2026; prior October 13 findings were deduplicated. Full-topic successful-check dates remain unchanged.; Retrieved all 14 records across 1 pages of the bounded ClinicalTrials.gov query, plus 7 named records. Selected relevant new/changed protocols were appraised; downloading all records does not establish exhaustive safety/results review.; Europe PMC original-literature discovery failed with HTTP 503 for this topic. Targeted primary-source web searches supplied a partial fallback. Worldwide literature, regulators, international registries and complete original conference/podcast recordings remain incomplete.; The new condition baseline remains incomplete. Preceding 90-day registry discovery and selected inherited pivotal context were checked; the full older clinical, label and behavioral/device evidence corpus has not been completed.; Saved iron, TOMAC, CBD and implanted/noninvasive stimulation records refreshed. No new RLS program result selected. October-issue TOMAC correction/full methods still need appraisal; a recent issue or mirror refresh was not treated as a new trial. Complete older drug/iron safety, augmentation, special-population and original conference baseline remains incomplete.

Informal sources and unresolved claims: Targeted RLS Reddit searches and the prior algorithm thread were deduplicated. Personal drug, device and food-trigger experiences do not establish a new clinical program or cure. No distinct new attributable rumor selected; full SOS/SLEEP recordings and broader informal signals remain gaps.

Sources checked:

Homepage and publication

The October 3 EloraTZP feature remains useful after thirteen days, with matched efficacy and harms. Newer regulatory actions and small studies do not supply a stronger compatible headline chart in the existing curated datasets. Retained after editorial review; reconsider at the next substantive run, favoring evidence quality and variety. Historical numerical plots retain their original values, populations and intervals. Public export excludes personal notes and identifying context. Release validators and native deployment status verify this background release; no browser QA is claimed. Publication receipt is recorded privately in state after success.